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Background/aim: To characterize the clinical course of noninvasive positive pressure ventilation (NIPPV) and high flow humidified
nasal cannula ventilation (HFNC) procedures; perform risk analysis for ventilation failure.
Material and methods: This prospective, multi-centered, observational study was conducted in 352 PICU admissions (1 month-18
years) between 2016 and 2017.
SPSS-22 was used to assess clinical data, define thresholds for ventilation parameters and perform risk analysis.
Results: Patient age, onset of disease, previous intubation and hypoxia influenced the choice of therapy mode: NIPPV was preferred in
older children (p = 0.002) with longer intubation (p < 0.001), ARDS (p = 0.001), lower respiratory tract infections (p < 0.001), chronic
respiratory disease, (p = 0.005), malignancy (p = 0.048) and immune deficiency (p = 0.026).
The failure rate was 13.4%. sepsis, ARDS, prolonged intubation, and use of nasal masks were associated with NIV failure (p = 0.001,
p < 0.001, p < 0.001, p = 0.025). The call of intubation or re-intubation was given due to respiratory failure in twenty-seven (57.5%),
hemodynamic instability in eight (17%), bulbar dysfunction or aspiration in 5 (10.6%), neurological deterioration in 4 (8.5%) and
developing ARDS in 3 (6.4%) children. A reduction of less than 10% in the respiration within an hour increased the odds of failure by
9.841 times (OR: 9.841, 95% CI: 2.0021–48.3742). FiO2 > 55% at 6th hours and PRISM-3 >8 were other failure predictors. Of the 9.9%
complication rate, the most common complication was pressure ulcerations (4.8%) and mainly observed when using full-face masks
(p = 0.047). Fifteen (4.3%) patients died of miscellaneous causes. Tracheostomy cannulation was performed on 16 children due to
prolonged mechanical ventilation (8% in NIPPV, 2.6% in HFNC)
Conclusion: Absence of reduction in the respiration rate within an hour, FiO2 requirement >55% at 6th hours and PRISM-3 score >8
predict NIV failure.
Key words: HFNC, noninvasive positive pressure ventilation, children, respiratory failure

1. Introduction
The introduction of new ventilation strategies at pediatric
intensive care (PICU) units broadened horizons from
conventional mechanical ventilation (MV) to noninvasive
ventilation (NIV) for children who require advanced
respiratory support. This alternative strategy improves

respiratory functions in children with acute respiratory
failure (ARF) by preserving intact airway reflexes while
avoiding the potential risks of endotracheal intubation
[1]. Facilitating early liberation from intubation is
another advantage especially for those delivering MV [2].
NIV improves oxygenation and effective ventilation by
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decreasing the work of breathing and unloading respiratory
muscles. The outcome is better oxygen delivery with
enhanced gas exchange and better ventilation/perfusion
ratio in patients with hypoxic and/or hypercapnic ARF
[3,4]. The efficiency has been studied in several clinical
conditions including acute pneumonia [5], bronchiolitis
[6], status asthmaticus [7] and post-extubation respiratory
failure [8]. Physiological studies also confirm the positive
influence on respiratory functions [9,10].
Noninvasive positive pressure ventilation (NIPPV)
techniques include continuous positive airway pressure
(CPAP) and bilevel positive airway pressure (BIPAP). They
are used in various etiologies [11–13] and the decision of
modality depends on the nature of respiratory failure:
CPAP for hypoxic ARF and smaller children, BIPAP for
older children with hypoxic and/or hypercapnic ARF [14].
Although not classified as positive pressure ventilation,
high flow humidified nasal cannula ventilation (HFNC)
is gaining interest in pediatric practice and is presented
as an alternative to CPAP in infants. HFNC enhances
oxygenation by providing anatomic oxygen reservoirs and
washing out the dead airway space [14]. It drives a CPAPlike effect at 6 L/min by generating a positive pressure
through the respiratory cycle [14,15].
NIV success relies upon appropriate patient selection,
choice of modality and experienced trained staff [14].
In contrary to adult consensus conference statements
[2,16], the guideline addressing the clinical applications
(criteria for initiation and/or discontinuation) in children
remain limited in this manner [17]. The decision of failure
is mostly left to the discretion of the treating physician.
Moreover, there is a varying range of discrepancy in interunit ventilation strategies between health-care facilities
[17]. This prospective, multicenter, observational study
was planned to characterize the clinical course of NIPPV
and HFNC implementations and observe success rates
in decreasing the necessity of mechanical ventilation or
re-intubation. The secondary outcome is to assess risk
analysis for respiratory failure and examine therapyattributed complications (if any).
2. Materials and methods
The study was conducted with the collaboration of eight
PICUs (universities or teaching hospitals governed by
the ministry of health) all across the country between
December 2016 and December 2017. The approval of
the local ethical committee was obtained from Akdeniz
University Faculty of Medicine, Clinical Research Ethics
Committee (no: 70904504/525, date: 11.18.2016). The
study was also registered at clinicaltrials.gov (approval
number: 70904504/525). All critically-ill children from
1 month to 18 years requiring NIPPV or HFNC in the
intensive care settings were enrolled in this study. We did
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not set any criteria for NIPPV or HFNC institution, therapy
discontinuation and the call of intubation. The clinical
decisions were led by the discretion of the attending senior
physician at each center.
A three-page case report form (CRF) was designed
to collect data. The patient demographics were grouped
according to the patient age (infants less than 12 months,
toddlers/preschool-aged children between 13 and 60
months, school-age/adolescents between 61 months to
18 years) and the underlying disease (including acute and
chronic settings). We categorized acute disease as i) lower
respiratory tract infections (LRTI) ii) conditions related to
bronchospasm including bronchiolitis and asthma attacks,
iii) upper respiratory tract infection (URTI): laryngitis and
laryngotracheobronchitis (croup), iv) clinically-proven
heart failure, v) central nervous system (CNS) related
disease: any disorder resulting in an incapability to sustain
airway maneuvers, vi) sepsis, vii) ARDS defined by the
Pediatric Acute Lung Injury Consensus Conference Group
(PALICC) [18], and finally vii) postoperative laryngeal
stridor. The underlying chronic conditions were classified
by Feudtner’s coding system [19]. The second page has
consisted of a multi-colon table to record the respiratory
rate (RR), heart rate (HR), systemic, mean and diastolic
blood pressures (BP), the pediatric risk of mortality-3 score
(PRISM-3) and pediatric logistic organ dysfunction score
(PELOD), Glasgow coma scale (GCS), comfort score, and
blood gas parameters. The device mode and settings, types
of masks used and drugs used for sedation (if given) were
obtained. We adjusted RR nd HR for age above the 99th
percentile to determine the abnormality above normal
limits to define tachypnea and tachycardia [20]. Data were
collected up to 5 days: immediately before commencing
respiratory support, at 1st, 2nd, 6th, 24th, 48th hours,
then daily. However, the statistical analysis regarding
NIV failure involved the first 48 h. The clinical outcome
including the cause of intubation or re-intubation (if so
the timing of intubation), the complications, the length
of ventilation therapy, PICU stay and hospitalization were
also recorded.
Children were divided into two main groups whether
if they achieved therapy success or not. Therapy failure was
defined as the necessity of endotracheal intubation or reintubation within the study period. In case of a failed trial,
the collaborators were asked to define the cause of failure
as patient-ventilator asynchrony, use of misfit interface,
excessive air leaks, neurological deterioration (GCS <
8 or deterioration over three units), risk of aspiration or
bulbar dysfunction (loss of swallowing), hemodynamic
alterations, presence of arrhythmia, pneumothorax, and
progression to ARF (worsening respiratory condition).
The definition of ARF was adapted from the criteria of
Teaque as an unsustainable alveolar exchange to meet the
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metabolic cellular demands [12]. CRF has also consisted
of several failure risk factors previously defined in the
literature, to set up criteria to anticipate ARF such as PaO2/
FiO2 < 200 [5,21] or FiO2 necessity over 80% at 1st hour
[22], blood gas pH < 7.25 after 2 h [23], failure to achieve
a decrease in RR within 6 h, clinically observed increased
work of breathing (respiratory score of 1–2 by Monachan’s
pediatric early warning system) [24], progression to
moderate/severe ARDS (oxygenation index > 8) [18].
Subgroup analyses were performed depending on the
mode of therapy and the therapy implementation (firstline therapy or rescue therapy). HFNC failures consisted
of children who delivered HFNC as respiratory support
throughout the study and encountered intubation or reintubation.
2.1. Statistical analysis
IBM SPSS Statistics for Windows, v. 22.0 (IBM Corp.,
Armonk, NY, USA) was used for statistics. Pearson chisquare and Fisher’s exact test were used to assessing
categorical data; Mann–Whitney U test and Student’s t-test
for nonnormally and normally distributed continuous
variables (after performing Shapiro–Wilks test to control
normality assumptions) We used repeated-measures
ANOVA with posthoc Bonferroni test to analyze the
change in the means of continuous variables at different
time points. The Friedman test alongise the Bonferroni
correction were used for nonparametric comparison of
parameters measured at different times. The receiver
operating characteristic (ROC) curve analysis was applied
to identify the cut-off points of continuous variables
with significant differences between groups and the
Youden index to determine the optimal cutoff point of
each variable of interest. Continuous variables were then
classified into positive or negative groups according to the
cutoff point. We then, performed a multivariate logistic
regression analysis to determine independent risk factors
associated with therapy failure. Data are expressed as n (%),
mean ± standard deviation (SD), or median (minimummaximum). P-value < 0.05 was considered statistically
significant.
3. Results
3.1. Patient characteristics
A total of 352 children of male gender predominance
(56.8%) with a median age of 18 months (1.5–204 months)
and the bodyweight of 10 kg (min-max: 2.1–120 kg) was
enrolled in the study. The distribution of age category was
infanthood in 152 patients (43.2%), toddlers/preschool era
in 119 (33.8%) patients and school-age/adolescents in 81
(23%) patients. LRTI and hypoxic ARF were the common
causes of NIV administration (47.4%, 67.9%; Table 1).
Overall, 71.6% of the population had an underlying
chronic condition involving (in decreasing order) cardiac

disease, neurological conditions, and immune deficiency
(25.6%, 21.9%, 7.1%; Table 2). The median duration of
NIV administration was 72 h (min-max: 36–120 hours).
3.2. Decision of modality and device selection
Table 3 presents the population demographics and
outcome measures according to treatment modality. Both
NIPPV and HFNC were used as first-line or rescue therapy
(rescue therapy: 48.8% versus 58.1%, p = 0.092). Several
factors acted upon the selection of ventilation mode such
as, patient age, duration of previous intubation, the nature
of acute and chronic disease. NIPPV was the preferred
modality in older children with longer intubation periods
(p = 0.002, p < 0.001), in an acute of setting of ARDS and
LRTI (p = 0.001, p < 0.001) and in an underlying condition
such as chronic respiratory disease, malignancy and
immune deficiency (p = 0.005, p = 0.048, p = 0.026). The
choice of method were based on the degree of age-adjusted
tachypnea (NIPPV: 65.3%, HFNC: 52.9%, p = 0.022) and
SpO2/FiO2 values (NIPPV: 175.24 ± 52.99, HFNC: 192.83 ±
55.23; p = 0.005), instead of blood gas pCO2 (NIPPV: 45.39
± 11.01 mmHg, HFNC: 43.55 ± 9.54 mmHg, p = 0.144).
The children delivering NIPPV were more likely to
receive treatment via specific noninvasive ventilation
devices (93.6%) with full-face masks (48%), nasal masks
(19.2%), and oronasal masks (11.2%).
3.3. Sedation procedures and complications
To optimize care, 46.9% of children received a sedation
procedure under assessment of comfort scores (Table 1).
The most frequent drugs were dexmedetomidine, ketamine,
and midazolam administered at intermittent bolus doses
(32.1%, 30.3%, and 30.3% respectively). Sedation sessions
were applied to children using (in decreasing order), fullface masks 55%, nasal masks 45.8%, nasal prong 45.3%,
and oronasal masks 42.9%.
A total of 35 (9.9%) complications were observed
regardless of therapy mode (NIPPV: 14.4% vs. HFNC:
7.5%; p = 0.063). The incidence varied between different
mask types: 25% in nasal masks, 11.7% in full-face masks,
8.3% in nasal prongs and 7.1% in oronasal masks. The
most common complication was pressure ulcerations
(skin/mucosa breakdown) (17/352, 4.8%). The ones who
failed their NIV sessions had increased complication rates
(p < 0.001).
3.4. Therapy failure and risk analysis
Forty-seven (13.4%) children were marked as NIV failures
and the majority had to be intubated within 48 h (in 4
children, the decision of failure extended beyond 48 h:
one in NIPPV and 3 in HFNC). Instead of the patient
characteristics (age, sex), the nature of acute respiratory
failure (hypoxic or hypercapnic), NIV modality (NIPPV/
HFNC) or the therapy institution (first-line/rescue
therapy), the acute onset of disease (sepsis and ARDS: p
= 0.001, p < 0.001) and the underlying chronic conditions
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Table 1. General demographics of the study population
Variable

N = 352

Variable

N = 352

239 (67.9%)

Hypercapnic ARF

113 (32.1%)

125 (35.5%)

HFNC

227 (64.5%)

159 (45.2%)

Rescue therapy

193 (54.8%)

PRISM-3 score*

5 (2-51)

GCS**

13.76 ± 1.67

PELOD score*

6 (2-50)

Comfort score**

23.06 ± 3.65

Dexmedetomidine

53/165 (32.1%)

Fentanyl

6/165 (3.6%)

Ketamine

50/165 (30.3%)

Paracetamol

2/165 (1.2%)

Midazolam

50/165 (30.3%)

Morphine

2 (1.2%)

Chloralhydrate

4/165 (2.4%)
Hospitalization*

14 (4-98)

Acute Respiratory Failure (ARF)
Hypoxic ARF
Mode of therapy, n (%)
NIPPV
Therapy implementation, n (%)
First-line therapy
ICU Scores

Sedoanalgesia (n=165, 46.9%)

Length of stay (days)
Intensive care*

8 (2-98)

*median (min - max); ** mean ± SD. Abbreviations: ARF: acute respiratory failure, NIPPV:
noninvasive positive pressure ventilation, HFNC: high flow humidified nasal cannula ventilation,
GCS: Glasgow coma scale
Table 2. Acute and Chronic Onset of Diseases
Acute onset of disease

The underlying chronic conditions

LRTI

167 (47.4%)

Cardiac disease a

90 (25.6%)

Bronchiolitis/asthma attack

61 (17.3%)

Neurological conditions

77 (21.9%)

URTI

12 (3.4%)

Immune deficiency

25 (7.1%)

Postoperative stridor

12 (3.4%)

Metabolic disease

22 (6.3%)
b

Heart failure

41 (11.6%)

Respiratory disease

Sepsis

30 (8.5%)

Genetic

19 (5.4%)

CNS-related

21 (6%)

Genitourinary

16 (4.5%)

ARDS

13 (3.7%)

Malignancy
Gastrointestinal disease

20 (5.7%)

11 (3.1%)
c

9 (2.6%)

Abbreviations: LRTI: lower respiratory tract infection, URTI: upper respiratory tract infection, CNS-related:
central nervous system related disease, ARDS: acute respiratory distress syndrome
a
Cardiac disease includes congenital heart disease; b Respiratory disease includes bronchopulmonary dysplasia;
c
Gastrointestinal disease involves hepatic and biliary system

(metabolic and genitourinary problems: p = 0.017, p =
0.048) were related to NIV failure (Table 4). These patients
had longer intubation period prior to NIV administration,
higher PRISM-3, PELOD scores and lower GCS (p <
0.001, p < 0.001, p < 0.001, p = 0.003, respectively). The call
of intubation/re-intubation was given due to respiratory
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failure in 27 (57.5%) children, hemodynamic instability
in 8 (17%), bulbar dysfunction or aspiration in 5 (10.6%)
children, neurological deterioration in 4 (8.5%) children
and developing ARDS in 3 (6.4%) children. The use of a
nasal mask during NIPPV was also associated with NIV
failure (15.2% versus 5.6%; p = 0.025).
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Table 3. The descriptive analysis of NIV modalities (HFNC–NIPPV).
NIPPV

HFNC

Age (months)*

27 (1.5–204) 14 (1.5–192)

Infanthood

46 (36.8%)

o
0.002

106 (46.7%)
0.001

NIPPV

HFNC

Bodyweight (kg)*

10.5 (3–120) 9 (2.1–100)

NIV duration (hours)*

72 (6–480)

p
0.004

52 (6–48024) 0.012

Previous intubation (hours)* 140 (28–726) 48 (25–1000) < 0.001

Toddlers/preschool age 36 (28.8%)

83 (36.6%)

School age/adolescents 43 (34.4%)

38 (16.7%)

Male gender, (n)

72 (57.6%)

128 (56.4%)

0.826

LRTI

76 (60.8%)

91 (40.1%)

< 0.001 Cardiac disease

Bronchiolitis/asthma

43 (34.4%)

108 (47.6 %)

0.017

URTI

-

11 (4.8%)

0.012

Postoperative stridor

4 (3.2%)

8 (3.5%)

ARDS

10 (8%)

Heart failure

10 (8%)

Sepsis
CNS-related

PRISM-3 score*

6 (2–38)

5 (2–51)

0.264

PELOD score*

6 (2–31)

8 (2–50)

0.240

19 (15.2%)

71 (31.1%)

0.001

Neurological condition

33 (26.4%)

44 (19.4%)

0.128

Metabolic disease

12 (9.6%)

10 (4.4%)

0.054

0.569

Genetic disease

6 (4.8%)

13 (5.7%)

0.713

3 (1.3%)

0.001

Respiratory disease

13 (10.4%)

7 (3.1%)

0.005

31 (13.7%)

0.113

Genitourinary disease

6 (4.8%)

10 (4.4%)

0.865

10 (8.8%)

19 (8.4%)

0.894

Gastrointestinal disease

3 (2.4%)

6 (2.6%)

0.896

5 (4%)

16 (7%)

0.248

Malignancy

7 (5.6%)

4 (1.8%)

0.048

Immune deficiency

14 (11.2%)

11 (4.8%)

0.026

Acute onset of disease

Underlying chronic conditions

Outcome
PICU stay (days)*

11 (2–98)

7 (2–69)

< 0.001 Hospital discharge (days)*

20 (5–98)

12 (4–95)

< 0.001

Tracheostomy (n)

10 (8%)

6 (2.6%)

0.021

8 (6.4%)

7 (3.1%)

0.140

Exitus, (n)

*median (min-max). Abbreviations; NIPPV: noninvasive positive pressure ventilation, HFNC: high flow humidified nasal cannula
ventilation, LRTI: lower respiratory tract infection, URTI: upper respiratory tract infection, ARDS: acute respiratory distress syndrome,
CNS related: central nervous system related, PICU: pediatric intensive care unit

Figures 1 and 2 present the vital parameters and blood
gas analysis in NIV failure (Figure 1a: Respiration rate,
Figure 1b: Heart rate, Figure 1c: Systolic blood pressure,
Figure 1d: Diastolic blood pressure, Figure 1e: Glasgow
coma scale, Figure 1f: Comfort score; Figure 2a: SpO2/FiO2,
Figure 2b: PaO2/FiO2, Figure 2c: Blood gas pH, Figure 2d:
Blood gas pCO2 in NIV Failure). NIPPV failures displayed
significant device settings: higher inspiratory pressure
(IPAP) requirement with lower tidal volumes at all times
(Table 5). On the contrary, the initial settings of flow-rates
in HFNC remained more or less the same regardless of
therapy success (p = 0.973).
ROC curve analysis for NIV failure has indicated the
cutoff values (calculated by the Youden index) for FiO2
>55% at the 6th hour and PRISM-3 score >8 (AUC: 0.762,
95% CI: 0.7100–0.809, sensitivity 89.87%, specificity
70.79% and AUC: 0.756, 95% CI:0.695–0.810, sensitivity:
86%, specificity: 77.2%). A multivariate logistic regression
was launched to define the deteriorating child at risk for
NIV failure and included the variables such as respiration
rate, FiO2 at the 6th hour, PRISM-3 score, ARDS, sepsis,
and metabolic andgenitourinary disease. The model
identified a less than 10% decrease in respiration in the 1st

hour (OR: 9.841, 95% CI: 2.0021–48.3742, p < 0.004), FiO2
nesessity >55% at 6th hours (p = 0.002, OR: 5.2936 95%
CI: 1.7964–15.5995, p = 0.002) and PRISM-3 score >8 as
independent risk factors for NIV failure OR: 3.9011 95%
CI: 1.3370–11.3827, p = 0.012).
3.5. Prognosis
Of forty-seven (13.4%) ventilation failures, 15 (4.3%)
children died of miscellaneous causes (time of death:
median 15.5 days, min-max: 4–32 days). Tracheostomy
cannulation was performed on 16 children due to
prolonged invasive mechanical ventilation (8% in NIPPV,
2.6% in HFNC)
4. Discussion
There were several outcomes in the current study. The
immediate effect of noninvasive ventilation on patients’
respiration was observed at the very early stages of
therapy: the successful trials were able to lower down their
RR at least 10% within an hour. The changes in ventilation
parameters appeared to be a significant indicator to
observe therapy response [25]. In a previous study from
Bakalli et al., children achieved success with a positive
predictive value of 88.2% (95% CI: 72.5%–96.6%), when
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Table 4. The descriptive analysis of NIV failure.
Variable

failure

NIV
success

p

Variable

NIV
failure

NIV
success

p

Age (months)*

36 (2–192) 16 (1.5–204) 0.137

PRISM-3 score*

13 (2–51)

5 (2–36)

<0.001

Bodyweight (kg)*

12 (2.1–60) 9.7 (2.7–120) 0.453

PELOD score*

14 (2–50)

6 (2–44)

<0.001

Male gender

28 (59.6%) 172 (56.4%)

0.682

GCS (mean ± SD)

13.21 ± 1.67 13.85 ± 1.66 0.003

Hypoxic ARF

34 (72.3%) 205 (67.2%)

0.483

Complications

15 (31.9%)

20 (6.6%)

<0.001

LRTI

25 (53.2%) 142 (46.6%)

0.397

Cardiac

4 (8.5%)

86 (28.2%)

0.004

Bronchiolitis/asthma

1 (2.1%)

60 (19.7%)

0.003

Neuromuscular

15 (31.9%)

62 (20.3%)

0.074

URTI

-

11 (3.6%)

NA

Metabolic

7 (14.9%)

15 (4.9%)

0.017

ARDS

6 (12.8%)

7 (2.3%)

<0.001 Genetic

3 (6.4%)

16 (5.2%)

0.478

Heart failure

4 (8.5%)

37 (12.1%)

0.471

Respiratory

3 (6.4%)

17 (5.6%)

0.515

Sepsis

11 (23.4%) 19 (6.2%)

0.001

Genitourinary

5 (10.6%)

11 (3.6%)

0.048

CNS-related

5 (10.6%)

16 (5.2%)

0.132

Gastrointestinal

3 (6.4%)

6 (2.0%)

0.105

Postoperative stridor

-

12 (3.9%)

NA

Malignancy

3 (6.4%)

8 (2.6%)

0.170

Immune deficiency

5 (10.6%)

20 (6.6%)

0.229

First-line therapy

22 (46.8%)

137 (44.9%)

Rescue therapy

25 (53.2%)

168 (55.1%)

Nasal mask

7 (15.2%)

17 (5.6%)

0.025

Oronasal mask

3 (6.5%)

11 (3.6%)

0.408

Full-face mask

11 (23.9%)

50 (16.4%)

0.210

Nasal Prong

27 (57.4%)

227 (74.4%) 0.016

Acute onset of disease

Underlying chronic disease

Therapy mode

Therapy implementation

NIPPV

22 (46.8%) 103 (33.8%)

HFNC

25 (53.2%) 202 (66.2%)

0.082

Device selection

0.808

Interfaces

Specific NIPPV device

18 (38.3%) 98 (32.1%)

MV with NIV mode

3 (6.4%)

Specific HFNC device

26 (55.3%) 202 (66.2%)

5 (1.6%)

0.072

Signs of respiratory failure
Tachypnea**

33 (70.2%) 167 (55.1%)

0.052

Bloodgas pH <7.25 (2nd hour) 2 (4.3%)

4 (1.3%)

0.186

SpO2/FiO2 < 200 (1st hour) 38 (82.6%) 148 (49.3%)

< 0.001 RR decline >10% (1st hour)

44 (93.6%)

178 (58.9%) <0.001

FiO2 > 80% (1st hour)

14 (37.8%) 27 (9.6%)

< 0.001 RR decline >10% (6th hour)

46 (97.9%)

77 (25.5%)

<0.001

26 (4–98)

< 0.001 Hospitalization*

32 (4–98)

13 (5–98)

<0.001

The length of stay (days)
PICU stay*

7 (2–87)

*median (min-max); ** Age-adjusted tachypnea; Abbreviations: NIV: noninvasive ventilation, ARF: acute respiratory failure, NIPPV:
noninvasive positive pressure ventilation, HFNC: high flow humidified nasal cannula ventilation, GCS: Glasgow coma scale, LRTI:
lower respiratory tract infection; URTI: upper respiratory tract infection, ARDS: acute respiratory distress syndrome, CNS-related:
central nervous system related, MV with NIV mode: conventional mechanical ventilation with noninvasive ventilation mode, RR:
respiration rate, PICU: pediatric intensive care unit

they were able to reduce their RR more than 10 respiration/
min in 2 h [25]. Similarly, Mayordomo-Colunga et al.
stated the absence of RR decline at 1st and 6th hours in
NIPPV failure [26]. Several models also predict HFNC
failure such as RR above the 90th percentile for age at
triage [1,27], no RR or HR change within 60 min [28]
and worsening pediatric early warning scores [29]. The
failure rate (13.4%) in this study was within the reported
ranges of 3% and 30% [3,8,30]. Neither the treatment
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modality (NIPPV/HFNC) nor the therapy institution
(first-line/rescue therapy) was associated with NIV
failure. Literature data suggest that longer intubation [3],
higher FiO2 requirement [3,5,31], PRISM-3 and PELOD
scores [31], hypoxic ARF, parenchymal lung disease and
ARDS [3,5,25,32] are recognized as potential risk factors.
However all of the published researches report different
cutoff values other than thresholds obtained in the current
study (PRISM-3 score > 8 and FiO2 requirement > 55 at
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Figure 1. a) Respiration rate in NIV failure; b) Heart rate in NIV failure; c) Systolic blood pressure in NIV failure; 1d) Diastolic
blood pressure in NIV failure; 1e) Glasgow coma scale in NIV failure; 1f) Comfort score in NIV failure.
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Figure 2. a) SpO2/FiO2 in NIV failure; 2b) PaO2/FiO2 in NIV failure; 2c) Blood gas pH in NIV failure; 2d) Blood gas pCO2 in NIV
failure.

6 hours). Our findings were lower than previous data: a
cut-off level of 10 for PRISM-3 in Bakalli’s research [25]
or FiO2 > 80% in the first hour [22], FiO2 > 57% [5], and
FiO2 > 60% [25].
Unlike literature data reporting pneumonia as the sole
factor for NIV failure [2,3], our findings pointed out sepsis
and ARDS. The impact of sepsis is a little-known subject
(mostly studied in malignancies) in the acute setting of
NIV [33–36]. ARDS, on the other hand, is a well-defined
challenge for therapy success [31]. In 2015, the PALICC
group stated the beneficiary effects of noninvasive
ventilation especially for an immune-compromised
child under the condition of close monitoring and
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presence of trained healthcare providers. However, the
recommendations were limited to the early ARDS stages;
they concluded not to delay intubation in case of severe
disease or no clinical improvement [18]. The current
study’s ARDS rates were relatively lower: 8% in NIPPV,
1.3% in HFNC sessions and approximately half of the
patients had to be intubated following the NIV-course
(46.2%, 6/13). Yet, our findings could not be attributed to
true incidence of ARDS due to the study’s observational
design. Further, larger scaled investigations are needed to
focus on ARDS and noninvasive ventilation.
Distinct characteristics regarding device settings
emerged from this study. Despite a steady IPAP increase,
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Table 5. The device settings in NIV failure.
Therapy failure
Variables

Therapy success

Time

Mean ± SD

Mean ± SD

p

Time
Initial
1. hour
2. hour
6. hour
24. hour
48. hour
< 0.001
Initial
1. hour
2. hour
6. hour
24. hour
48. hour
0.999
Initial
1. hour
2. hour
6. hour
24. hour
48. hour
0.257
Initial
1. hour
2. hour
6. hour
24. hour
48. hour
0.999
Initial
1. hour
2. hour
6. hour
24. hour
48. hour
0.999

Mean ± SD
15.63 ± 4.73
15.88 ± 4.99
17.01± 5.26
16.44 ± 5.44
17.01 ± 5.82
18.80 ± 5.29

Mean ± SD
12.77 ± 4.19
12.38 ± 3.21
12.93 ± 4.06
13.03 ± 4.03
12.88 ± 4.12
12.64 ± 4.48
0.200
5.57 ± 1.07
5.57 ± 0.99
5.62 ± 1.07
5.68 ± 1.09
5.67 ± 1.15
5.77 ± 1.15
0.853
55.98 ± 17.76
50.54 ± 11.21
49.46 ± 9.91
49.13 ± 9.45
48.35 ± 9.72
45.06 ± 8.24
<0.001
0.64 ± 0.22
0.65 ± 0.22
0.65 ± 0.22
0.64 ± 0.22
0.66 ± 0.21
0.67 ± 0.21
0.416
2.51 ± 1.45
2.57 ± 1.54
2.56 ± 1.52
2.57 ± 1.51
2.54 ± 1.54
2.37 ± 1.56
0.416

Initial

6.76 ± 1.86

7.81 ± 1.81

0.049

1. hour

7.04 ± 1.69

7.83 ± 1.88

0.138

2. hour

6.62 ± 1.69

7.81 ± 1.72

0.025

6. hour

6.59 ± 1.67

7.81 ± 1.64

0.017

24. hour

6.74 ± 1.28

7.85 ± 1.64

0.034

48. hour

7.05 ± 1.55

7.74 ± 1.37

0.387

NIPPV Therapy

IPAP

p

EPAP /PEEP

p

FiO2 (%)

p

Inspiration time

p

Rise time

p

Tidal volume
(mL/kg)

5.58 ± 0.84
5.61 ± 0.78
5.71 ± 1.21
5.59 ± 0.87
5.80 ± 1.08
5.82 ± 0.87
68.89 ± 22.20
64.12 ± 18.05
56.25 ± 13.60
59.41 ± 14.78
58.93 ± 16.66
56.50 ± 7.47
0.66 ± 0.24
0.66 ± 0.25
0.68 ± 0.25
0.63 ± 0.20
0.62 ± 0.19
0.69 ± 0.18
2.68 ± 1.47
2.68 ± 1.47
2.65 ± 1.53
2.78 ± 1.53
2.73 ± 1.63
2.1 ± 1.28

0.013
0.006
0.002
0.015
0.007
0.001
0.923
0.705
0.913
0.993
0.555
0.676
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.819
0.906
0.722
0.852
0.551
0.814
0.801
0.954
0.961
0.792
0.873
0.752
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Table 5. (Continued).
p

Leakage

p

Mandatory rate

p

0.448

0.752

Initial

20.31 ± 12.21

29.88 ± 18.83

0.076

1. hour

20.31 ± 12.04

27.9 ± 17.69

0.200

2. hour

22.07 ± 12.64

30.12 ± 18.82

0.194

6. hour

23.43 ± 14.52

29.26 ± 18.93

0.478

24. hour

27.42 ± 16.75

28.61 ± 18.44

0.927

48. hour

22.63 ± 13.42

29.83 ± 19.59

0.350

0.413

0.570

Initial

23.44 ± 5.40

1. hour

24.33 ± 7.30

22.45 ± 6.40

2. hour

22.36 ± 4.94

6. hour

25.31 ± 8.01

21.3 ± 4.78

0.146

24. hour

24.55 ± 9.06

20.8 ± 4.55

0.355

48. hour

24 ± 8.07

20.7 ± 4.51

0.350

22.0 ± 5.46
21.54 ± 5.26

0.304

0.677
0.502
0.727

0.283

HFNC therapy

Flow rate

Initial

17.27 ± 7.83

17.29 ±7.80

0.973

1. hour

18.42 ± 8.71

17.79 ± 7.78

0.739

2. hour

18.01 ± 7.08

17.68 ± 7.62

0.529

6. hour

19.67 ± 8.71

17.03 ± 7.59

0.085

24. hour

20.90 ± 9.62

15.64 ± 7.12

0.008

14.39 ± 7.43

0.007

48. hour
p

FiO2 (%)

< 0.001

0.027
67.63 ± 18.59

1. hour

68.75 ± 19.96

2. hour

67.35 ± 18.72

48.64 ± 12.94

< 0.001

6. hour

68.01 ± 18.59

47.78 ± 12.15

< 0.001

48. hour

50.73 ± 14.42

< 0.001

Initial

24. hour
p

20.88 ± 10.11

49.88 ± 14

60.77 ± 20.9
62.78 ± 19.54

0.182

< 0.001

43.36 ± 10.99

0.002

41.29 ± 10.54

< 0.001

< 0.001

Abbreviations: ARF: acute respiratory failure, NIPPV: noninvasive positive pressure ventilation,
IPAP: inspiratory positive airway pressure, EPAP: expiratory positive airway pressure, PEEP:
positive end expiratory pressure, FiO2: fraction of inspired oxygen, HFNC: high flow humidified
nasal cannula ventilation.

we noted steady end-expiratory pressure (EPAP/PEEP)
levels in children receiving NIPPV even if they demanded
higher oxygen to improve work of breathing. EPAP and
PEEP are two synonymous parameters known to minimize
alveolar collapse and improve oxygenation [4]. Apparently,
the choice of intervention favored endotracheal in hypoxic
patients instead of elevating EPAP/PEEP elevation in
hypoxic patients. We think this outcome might be the
reflection of PALICC recommendations on ARDS ‘not
delaying intubation in the absence of clinical improvement’
[18].
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Age, length of previous intubation, underlying
conditions (acute and chronic settings) were noted to play
a role in the decision of ventilation modality. HFNC was
the preferred method of NIV in smaller children acquiring
upper respiratory system problems and bronchiolitis/
asthma attacks. NIPPV, on the other hand, was mostly
used in older children with prolonged intubations, primary
parenchymal lung disease (pneumonia, ARDS, chronic
lung disease), malignancy, and immune deficiency.
Complex chronic conditions inevitably influence the
ventilation strategies [8,19,33]. SCARF (early CPAP in
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acute respiratory failure) study is a recent, randomized,
controlled study performed in children with a highrisk combination of impaired immunity and ARF [37].
Given the evidence from SCARF study, NIPPV remained
as a reserved ventilation method for more distressed
population with malignancy or immune deficiency who
possess greater risks for endotracheal intubation. Our
findings shared a common ground with the SCARF study:
NIPPV was chosen for more tachypneic and hypoxic
(lower SpO2/FiO2) children who required higher FiO2
and longer therapy sessions in the study centers. Of note,
children receiving NIPPV were more likely to require
tracheostomy cannulation when they were intubated
or re-intubated, even their initial PRISM-3 or PELOD
scores were similar. This outcome verified the fact that,
the nature of underlying problem were more important
when compared to disease severity. The findings were
also supported by two previous investigations that
demonstrated any insignificance between PIM-2 scores
and ventilation failure [22,33].
NIPPV implementations confront certain challenges
amongst the youth such as air leakages, higher respiration
rates, and reduced respiratory efforts to achieve patientdevice synchrony. Therefore, the success depends on the
appropriate device selection, including interface, circuit,
device, and device settings [12]. Our local practices favored
the application of specific noninvasive ventilator devices
(capable of compensating high leakage) with the use of fullface masks. Recent advances in the manufacturing industry
have resulted in different-sized masks, which enable more
applicable, patient-friendly utilization at all ages [8]. Fullface masks provide both comfort (by spreading the maskfit pressure over a larger surface beyond the nose) and
fewer pressure-related complications than oronasal masks
[12]. Besides, the efficiency are shown in terms of breathing
pattern and gas exchange as much as the oronasal masks
[12]. The practice regarding the selection of interfaces in
the current study was consistent with the PALICC group
who have suggested the application of full-face or oronasal
masks in pediatric ARDS for effective ventilation [18].
Several studies emphasized the impact of nasal masks
[12,38]. These masks are noted to have several advantages
such as more comforting patient-friendly use, fewer gastric
distension, better feeding tolerance, safer for aspiration
[12], and lower risks of NIV failure [38]. Opposing this
hypothesis, we observed significant complication and
failure rates with the use of nasal masks. One possible
explanation might be the mouth breathing of the youngster
as a result of frequent nasal obstruction caused by viral
infection and inflammation that could limit the efficacy of
noninvasive ventilation.
The total complication rate was 9.9%. Surprisingly, they
occurred mostly in failure trials instead of successfullymanaged children who received ventilation support for

more extended periods. Altered consciousness due to
hypoxemia or hypercapnia, immobility and hemodynamic
alterations in critically-ill children might be the underlying
cause of this outcome. Skin/mucosa breakdown appeared
to be the most common complication overall (4.8%),
mainly observed at full-face masks. The incidence was
within the reported range between 4% and 27% [4,39].
The study had several limitations. First of all, the
scope of this research consisted of clinical observations
on ventilation techniques and daily implementations.
Thus we did not set any criteria for the decision of therapy
institution or NIV failure. The call of intubation might
have created subjectivity due to individual approaches of
the collaborators. Secondly, we did not gather information
on the decision-making process of the attending
physicians to make any assumptions (e.g., the underlying
factors for low ARDS percentage or the absence in EPAP/
PEEP change throughout the ventilation session). The data
on sedation sessions were also limited; whether if they
were based on sedation protocols at each participating
PICU or not. Despite the limitations, the prospective,
observational, multi-centered nature of the study enabled
us to observe the daily practice of NIV implementations
and interpret a wide range of variations at multiple PICUs.
The study also allowed us to improve our knowledge of
ventilation techniques and to design local protocols to
identify the ones at risk for developing respiratory failure.
Furthermore, NIV failure was defined as intubation or reintubation within 48 h [6]. Five days of study period has
given the opportunity to observe whether the decision of
failure has extended over 48 h or not. Only 4 children have
failed their ventilation sessions after 48 h, therefore the
statistics have included the first two days of the ventilation
sessions.
5. Conclusion
Age, acute disease, length of previous intubation, and
the degree of hypoxemia adjudicated the selection of
therapy modality. The failure rates were 17.6 and 11% at
NIPPV and HFNC deliveries. A less than 10% decline in
respiration within an hour, FiO2 requirement >55% at the
6th hour, and a PRISM-3 score >8 were three independent
risk factors related to NIV failure. Instead of patient
demographics (age, sex, and nature of respiratory failure),
therapy modality (NIPPV or HFNC) and the institution
of NIV as a first-line or rescue therapy, the nature of the
acute disease (sepsis and ARDS), prolonged intubation
prior to NIV, and the use of nasal masks were associated
with therapy.
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